ReviewCurrent neurology and neuroscience reports2010
Immunotherapy approaches for malignant glioma from 2007 to 2009.
Review in Current neurology and neuroscience reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.Cancer immunology, immunotherapy : CII · 2021Article
- Circular RNA CircHIPK3 Elevates CCND2 Expression and Promotes Cell Proliferation and Invasion Through miR-124 in Glioma.Frontiers in genetics · 2020Article
- Insights into molecular therapy of glioma: current challenges and next generation blueprint.Acta pharmacologica Sinica · 2017Review
- Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.Journal of immunology research · 2017Review
- Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.Cancer gene therapy · 2015Article
- Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.Cancer immunology research · 2015Article
- OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.Molecular cancer · 2015Article
- Immunotherapy for malignant glioma.Surgical neurology international · 2015Article
- Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas.PloS one · 2014Article
- Diffuse intrinsic pontine glioma: time for therapeutic optimism.CNS oncology · 2014Review
- Genetically modified T cells to target glioblastoma.Frontiers in oncology · 2013Review
- Interferon regulatory factor 3 alters glioma inflammatory and invasive properties.Journal of neuro-oncology · 2013Article
- Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.Anticancer research · 2013Article
- Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.Current pathobiology reports · 2013Article
- Generation and immunologic functions of Th17 cells in malignant gliomas.Cancer immunology, immunotherapy : CII · 2013Article
- Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials.Neurologia medico-chirurgica · 2013Review
- Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.Human gene therapy · 2012Article
- Passive immunotherapeutic strategies for the treatment of malignant gliomas.Neurosurgery clinics of North America · 2012Review
- Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity.Cancer immunology, immunotherapy : CII · 2012Article
- Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Current cancer drug targets · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Malignant glioma is a deadly disease for which there have been few therapeutic advances over the past century. Although previous treatments were largely unsuccessful, glioma may be an ideal target for immune-based therapy. Recently, translational research led to several clinical trials based on tumor immunotherapy to treat patients with malignant glioma. Here we review 17 recent glioma immunotherapy clinical trials, published over the past 3 years. Various approaches were used, including passive transfer of naked and radiolabeled antibodies, tumor antigen-specific peptide immunization, and the use of patient tumor cells with or without dendritic cells as vaccines. We compare and discuss the current state of the art of clinical immunotherapy treatment, as well as its limited successes, pitfalls, and future potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.